Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists.

By Xu, Cheng, Chen +3Oct 28, 2026

Score█████░░░░░5.3

Key numbers

95% CI 1.47-1.89
900,000 participants
134,138 participants

Caveats

Preprint; not yet peer reviewed.

VerdictA leading story on any desk.

Read the original PDF

Abstract

Background: Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods: We analysed genome-wide data on seven disorders from FinnGen and UK Biobank (over 900,000 participants) by genomic structural equation modelling, tested five endocrine and metabolic exposures by Mendelian randomisation, mapped heritability onto 110,020 connective-tissue cells, and pooled serious adverse events from 210 placebo-controlled trials of incretin receptor agonists (134,138 participants). Findings: The disorders formed two replicated heritable axes: tenosynovial (carpal tunnel syndrome, trigger finger, de Quervain tenosynovitis; 61 loci) and fibro-capsular (frozen shoulder, Dupuytren's disease, plantar fascial disorder; 42 loci). Each SD higher genetically predicted body mass index increased the odds of carpal tunnel syndrome (odds ratio [OR] 1.67, 95% CI 1.47-1.89; P = 6.9 x 10^-16) and decreased those of Dupuytren's disease (0.57, 0.46-0.71; P = 8.7 x 10^-7), whose heritability concentrated in lesional POSTN+ fibroblasts. Incretin receptor agonists increased serious fibro-capsular events (Peto OR 3.88, 1.83-8.25; P = 4.1 x 10^-4), including frozen shoulder (4.16, 1.50-11.54) and Dupuytren's disease (3.58, 1.17-10.93), but not tenosynovial events (1.02, 0.60-1.75). Interpretation: Hand and shoulder soft-tissue disease comprises two genetically distinct axes with opposite responses to adiposity. It identifies frozen shoulder and Dupuytren's disease as musculoskeletal pharmacovigilance targets for the millions receiving incretin receptor agonists. Funding: Health Commission of Hubei Province (WJ2023F086) and Department of Science and Technology of Hubei Province (2024BCB059).

Z. Xu, J. Cheng, X. Chen, J. Luo, X. Zhu, X. Guo

The editor's rubric

Heuristic review

Leverage3 / 5: A method or resource many groups across the field will adopt within a year.; 10% of this desk’s rubric
Magnitude3 / 5: Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.; 20% of this desk’s rubric
Evidence5 / 5: Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale.; 32% of this desk’s rubric
Novelty2 / 5: A new combination of known ideas.; 8% of this desk’s rubric
Trajectory2 / 5: Some room to improve with obvious engineering.; 5% of this desk’s rubric
Stakes3 / 5: Meaningful benefit to many people within a few years.; 25% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	███░░3/5	10%	A method or resource many groups across the field will adopt within a year.
Magnitude	███░░3/5	20%	Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.
Evidence	█████5/5	32%	Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale.
Novelty	██░░░2/5	8%	A new combination of known ideas.
Trajectory	██░░░2/5	5%	Some room to improve with obvious engineering.
Stakes	███░░3/5	25%	Meaningful benefit to many people within a few years.

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: breadth (many tasks); gains (efficacy); design (randomized, placebo-controlled); verification (confidence interval, independent replication); stakes (global scale, major disease, prevention or cure).

How the score was computed

rank-2026-10-18

Score█████░░░░░5.3

Score = 10 × (80% × adjusted merit / 10 + 10% × attention + 10% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 7.0 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 5.5 / 10; Shrunk toward the desk prior by editor confidence (48%).
Attention: 0%; Citations, upvotes, points, mentions.
Freshness: 92%; Half-life decay since publication.

Citations0 (reference 20, via semantic-scholar, Oct 29, 2026, 06:17 UTC)

The record

Reviewed by heuristic-v10 on Oct 29, 2026, 06:17 UTC. Paper type: clinical.
Categories: genetic and genomic medicine
BRIEF, No.1 in the Medicine edition of October 29, 2026.